Is there a correct time to begin treatment of multiple myeloma?

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026

Bulge Progenitor Cells: A Promising Frontier in Hair Follicle Regeneration and Clinical Translation.

Stem cell reviews and reports·2026

Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation.

Bone marrow transplantation·2026

A step-wise, deterministic and fatal mouse model of myeloid neoplasm with spontaneous acquisition of patient-relevant RTK-RAS mutations.

Oncogene·2026

Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity.

Nature communications·2026

Related Experiment Videos

Is there a correct time to begin treatment of multiple myeloma?

Related Concept Videos

Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients.

Monoclonal proteins in neuropathy.

Immunohistochemical characterization of amyloid proteins in sural nerves and clinical associations in amyloid neuropathy.

Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease.

Current concepts on monoclonal gammopathies.

Mu-heavy chain disease: presentation as a benign monoclonal gammopathy.

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Surveying survival: benchmarking acute myeloid leukemia outcomes without transplant.

Measurable residual KMT2A partial tandem duplication before allogeneic stem cell transplantation in acute myeloid leukemia.

Normal platelet function in a patient with ARHGEF1 deficiency.

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials.

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Fulminant hyperammonemia during intensive chemotherapy in the setting of previously unrecognized partial ornithine transcarbamylase deficiency.

Management of glioblastoma in the elderly.

Bulge Progenitor Cells: A Promising Frontier in Hair Follicle Regeneration and Clinical Translation.

Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation.

A step-wise, deterministic and fatal mouse model of myeloid neoplasm with spontaneous acquisition of patient-relevant RTK-RAS mutations.

Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity.

Related Experiment Videos

Is there a correct time to begin treatment of multiple myeloma?

Related Concept Videos

Related Articles